#Japan #Tokyo #Eisai #Lemborexant #E2086

Eisai's Contributions to Sleep Medicine at World Sleep 2025

Eisai Co., Ltd., headquartered in Tokyo and led by CEO Haruo Naito, is set to make a substantial impact at the upcoming World Sleep Congress 2025, taking place in Singapore from September 5 to 10. The organization is scheduled to present a total of 11 clinical presentations, focusing primarily on its pioneering sleep medications: Lemborexant and the newly developed E2086, an orexin receptor agonist.

Lemborexant: A Proven Ally in Insomnia Treatment

One of the highlights will be discussions surrounding Lemborexant (marketed as DAYVIGO®), a selective orexin receptor antagonist that has shown encouraging results across various populations. Specifically, the company will share findings from a Phase IV clinical study titled the SELENADE Study, which investigates the efficacy of Lemborexant in patients dealing with insomnia alongside major depressive disorder or bipolar disorder. This research is pivotal as it sheds light on how Lemborexant can potentially address significant symptoms faced by this specific group of individuals.

Through targeted posters and oral presentations, Eisai will delve into multiple aspects of Lemborexant's performance:

• - A poster detailing findings from Indian adult patients outlines safety and efficacy based on a multicenter real-world study.
• - Additional presentations will address sleep state misperception, highlight the impacts on gut microbiota composition during treatment, and provide follow-up results from randomized trials in regions like South Korea and China.

Introducing E2086: A New Player in Narcolepsy Treatment

Eisai is not only committed to developing medications for insomnia but is also focused on addressing narcolepsy, particularly type 1. At the World Sleep 2025, Eisai will present groundbreaking data on E2086, a selective orexin 2 receptor agonist. This novel drug has demonstrated promising results in initial studies by significantly increasing periods of wakefulness while simultaneously reducing the incidence of cataplexy in narcoleptic patients. Such advancements in treatment are crucial as narcolepsy poses a chronic challenge characterized by excessive daytime sleepiness. In exploring the effectiveness of E2086, Eisai aims to harness orexin receptor activity, thereby potentially improving the quality of life for patients suffering from this disorder.

Engaging in Scholarly Discourse

Beyond data presentation, Eisai will host a symposium titled RISE – Regional Insights in Sleep Excellence on September 8. This session will feature discussions on evolving national guidelines regarding insomnia management, specifically focusing on the 2025 Thailand/Thai Framework.

Additionally, insights drawn from the SELENADE Study regarding the real-world application of Lemborexant in Japan will be shared, further demonstrating Eisai’s commitment to enhancing treatment practices in sleep medicine.

Eisai's Commitment to Neurology

Eisai places a critical emphasis on neurology as a significant therapeutic area ripe for innovation, especially concerning sleep disorders like insomnia and narcolepsy. Their mission focuses on producing groundbreaking products that address high unmet medical needs within this sector—aiming not only to enhance treatment outcomes but also to enrich the lives of patients and their families.

Eisai's presentations at the World Sleep Congress signify its steadfast dedication to science and innovation in sleep medicine. Given the substantial global burden of sleep disorders, this congress serves as an ideal platform for the company to share its advancements and gather insights from fellow experts to improve therapeutic approaches.

In conclusion, as Eisai prepares to showcase its findings, it illustrates a robust position at the intersection of research and practical treatment, propelling the understanding and innovation needed in the realm of sleep health.